Selective androgen receptor modulator
RAD-140 (Testolone)
RAD-140 (Testolone) after one dose: 50% at ~2.5 days, 25% at 5 days, 12.5% at 7.5 days.
Drawn from the half-life in the app's model, ~2.5 days. The model's figures
- Compound
- RAD-140 (Testolone)
- Symbol
- RAD
- Family
- SARMs
- Parts
- 13
- References
- 22
- Checked
- Last reviewed . Sources are listed below.
Overview
RAD-140, also called testolone, is an oral, nonsteroidal selective androgen receptor modulator (SARM) reported by Miller and colleagues, with authors listed at Radius Health, in ACS Medicinal Chemistry Letters (online 2010, issue dated 2011).3,4 The paper's PubMed summary calls it "a potent, orally bioavailable, nonsteroidal selective androgen receptor modulator (SARM)".3 Wagener and colleagues of the German Sport University Cologne (Metabolites, 2022) describe it as "a so-far unapproved SARM which is prohibited by WADA for its performance-enhancing effects".2
Searching PubMed on 16 November 2026 for RAD140, RAD 140, RAD-140, testolone or Testalone returned 49 records. Among the titles of those records, one reports a clinical trial of RAD140 in patients, a phase 1 study in breast cancer, and the others include case reports of liver and heart injury, laboratory detection and metabolism studies, and studies in animals and cells.1 ClinicalTrials.gov, searched for RAD140 on 16 November 2026, returned one study, NCT03088527, a phase 1 study in postmenopausal women with hormone receptor positive breast cancer.5
How it works
Wagener and colleagues write that "what all SARMs have in common is their agonistic effect on the androgen receptor (AR), while being tissue-selective".2 The same paper summarises the 2011 report on RAD140: "Preclinical data in rats and monkeys showed anabolic effects on muscle while showing a reduced effect on prostate growth when compared to testosterone".2 Yu and colleagues, with authors listed at Radius Health (Clinical Cancer Research, 2017), evaluated RAD140 in in vivo and in vitro models of AR/ER+ breast cancer and report that "RAD140 bound AR with high affinity and specificity and activated AR in breast cancer but not prostate cancer cells" and that oral administration "substantially inhibited the growth of AR/ER+ breast cancer patient-derived xenografts (PDX)".6
Animal studies
In female mice given RAD140 5 mg/kg for 10 weeks, Brown and colleagues (Clinical and Experimental Pharmacology and Physiology, 2023) reported that supplementation "increased frailty status and mortality risk in the young and adult treated groups compared to the controls (p ≤ 0.042)" and that it "failed to improve strength in female mice".7 The same paper reported decreased adaptive potential in young mice (p = 0.040) but not adult mice (p = 0.688), and torque did not differ between groups after 2 to 3 weeks of recovery (p ≥ 0.135).7 In 21 male and 15 female C57BL/6 mice aged 23.7 to 25.5 months given RAD140 5 mg/kg/day or placebo for 6 weeks, Heinze and colleagues (Mechanisms of Ageing and Development, 2025) reported no difference in frailty, "preserved lean mass (p = 0.024) and bone mineral density (p = 0.004)" and lower serum interleukin-6 (p = 0.043) in the treated males, and no such benefit in body composition or inflammatory markers in females.8 In both sexes grip strength, fat mass and skeletal muscle genes were unaffected.8 In young male Sprague-Dawley rats given RAD140 in drinking water (10 per group), Puskas and colleagues (Physiological Reports, 2025) reported a marked increase in muscle weight in the RAD140 overload group that was "not statistically different from the" vehicle overload group, fibre cross-sectional area "significantly elevated" in the RAD140 control group against the vehicle control group, and that RAD140 "did not impact cortical or trabecular bone structural morphometric properties following 14 days of treatment".9
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~2.5 days
- Bioavailability
- 95%
- Typical dose
- 10–25 mg/day
- Route
- Oral
- Time to peak
- ~2 h
The app lists the half-life of RAD-140 as about 60 hours (2.5 days), and the phase 1 trial in 22 women with metastatic breast cancer reported a half-life of 44.7 hours.1 The trial authors wrote that this half-life "supported QD dosing", and Wagener and colleagues cite it as "a half-life of 45 h".1,2
| Parameter | Value | Note |
|---|---|---|
| Half-life, app's figure | ~2.5 days (60 hours) | From the app's data; no measurement behind it is cited here |
| Half-life, phase 1 trial1 | 44.7 hours | 22 women with ER+/HER2- metastatic breast cancer, 50, 100 or 150 mg once daily |
| Time to peak, app's figure | ~2 hours | From the app's data |
| Time to peak, sources | No plasma figure reported in the sources listed here | In urine, RAD140 concentration reached its maximum 2 to 6 hours after ingestion of 1, 10 or 50 μg in healthy men2 |
| Bioavailability, app's figure | 95% | From the app's data |
| Bioavailability, sources | No percentage reported in the sources listed here | The PubMed summary of the 2011 report says "orally bioavailable"3 |
| Duration of activity, app's figure | ~5 days (120 hours) | From the app's data; the sources listed here give no figure |
| Route | Oral | The trial's RAD140 was "supplied as formulated drug-in-capsules for oral administration"5 |
In a micro-dose study of 30 healthy adult men, Wagener and colleagues measured RAD140 in urine, not blood.2 RAD140 was detectable "up to 29 days for a single 50 μg application", and "when taken 24 h apart, RAD140 shows accumulation over the five application days": at 50 μg the average value 2 h after the fifth dose was 2.4-fold the value 2 h after the first (3.0 ng/mL vs. 7.3 ng/mL).2 A detection time in urine is not a half-life.
The chart below is a modelled curve built from the app's half-life of 60 hours and time to peak of 2 hours, not measured concentrations; the once-daily interval is the schedule of the phase 1 trial, whose own half-life was 44.7 hours.1
Level over 4 weeks
Level, as a share of the peak after one 100 mg dose
As studied: once daily1.
An illustration from a pharmacokinetic model using a half-life of 60 hours (2.5 days). It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| LoRusso and colleagues, 20221 | Phase 1 first-in-human dose escalation (3 + 3 design) with a pharmacokinetic expansion cohort; no masking5 | 22 postmenopausal women with ER+/HER2- metastatic breast cancer (21 AR+), heavily pretreated | 50 mg (n = 6), 100 mg (n = 13) or 150 mg (n = 3) once daily; length not given in the PubMed summary | Half-life 44.7 hours; grade 3/4 adverse events in 16 (72.7%); 1 partial response at 100 mg/day; clinical benefit rate at 24 weeks 18.2%; median progression-free survival 2.3 months |
| Wagener and colleagues, 20222 | Six micro-dose urine excretion studies, single dose or five daily doses, urine analysed by LC-HRMS/MS | 30 healthy adult men, 5 per study | 1, 10 or 50 μg ingested in drinking yoghurt, once or on 5 consecutive days | Urinary RAD140 peaked 2 to 6 hours after ingestion and was detectable for up to 29 days after a single 50 μg dose; 2.4-fold higher 2 hours after the fifth daily 50 μg dose than after the first |
| Barbara and colleagues, 2020 (case report)10 | One patient; two products taken in turn | 52-year-old man who reported drinking bourbon and beer daily and using marijuana | Alpha Bolic, 2 capsules daily (10 mg RAD-140 each) for 4 weeks, then Alpha Elite, 2 capsules daily (7.5 mg RAD-140 and 5 mg LGD-4033 each) for 3 weeks | Biopsy: diffuse centrilobular canalicular cholestasis; liver enzymes returned to normal about 3 months after stopping both products |
| Leung and colleagues, 2022 (case report)11 | One patient | 24-year-old man | Up to 15 mg daily of RAD-140 for 5 weeks; also an acetaminophen, aspirin and caffeine product as needed | Cholestatic liver injury, peak total bilirubin 38.5 mg/dL; authors report symptoms and liver injury resolved after cessation; liver tests markedly improved at the most recent visit |
| Ladna and colleagues, 2023 (case report)12 | One patient | 26-year-old man with no past medical history | RAD140 (Testalone) workout supplement; dose not given in the report | AST 51 IU/L, ALT 243 IU/L, total bilirubin 4.9 mg/dL on presentation; hospitalised 4 days; AST, ALT and total bilirubin normal 1 month after discharge |
| Perananthan and George, 2024 (case report)4 | One patient | 43-year-old man; no other supplements reported | RAD-140 bought online, used for 2 months, stopped 1 week before the first doctor visit; dose not given | Total serum bilirubin 708 micromol/L at hospital admission; liver biochemistry back within reference ranges 5 months after stopping |
| Padappayil and colleagues, 2022 (case report)13 | One patient | 32-year-old man with type 1 diabetes, past cocaine and heroin use, on buprenorphine | RAD-140 bought online, dose not given; last use the day before hospital admission | Troponin I peaked at 100.5 ng/mL on hospital day 3; ejection fraction 45-50% on day 2 and 55-60% on day 7; discharged on day 8 |
| Schwartzman and colleagues, 2024 (case report)14 | One patient | 16-year-old boy | One dose of a product in a "RAD-140" fitness program; strength not given in the report | Troponin 4,690 ng/L, then 6,066 ng/L 2 hours later; treated with intravenous immunoglobulin and steroids; troponin normal at 2 weeks; cardiac MRI at 4 months showed minimal enhancement; echocardiogram normal at 8 months |
| Chong and colleagues, 2024 (case report)15 | One patient; three supplements analysed | 40-year-old man | 6 months of supplements that contained RAD-140, MK-677 and cardarine, plus undisclosed hormones | Bilateral gynecomastia and hypogonadotropic hypogonadism; full resolution after stopping the supplements |
The case reports describe one person each, and several of them involve other products or substances as well, such as LGD-4033, daily alcohol, MK-677 and cardarine, or buprenorphine.10,15,13 The authors of the Alpha Bolic and Alpha Elite report note that the products may have contained another unapproved substance not reported by the manufacturer in the drug label.10 The registry entry for the trial describes a first-in-human phase 1 study with a dose escalation part and a safety expansion part, 20 enrolled, status completed, start 23 October 2017 and completion 24 September 2020, with no results posted.5
Deeper analysis: the phase 1 trial of RAD140 in breast cancer
Who and how. LoRusso and colleagues, with the first author at Yale Cancer Center (Clinical Breast Cancer, 2022), reported a 3 + 3 dose escalation with a pharmacokinetic expansion cohort in postmenopausal women with ER+/HER2- metastatic breast cancer.1 Serum sex hormone-binding globulin and prostate-specific antigen were used as surrogate markers of androgen receptor engagement.1
Sponsor and author ties. Five of the ten authors (Bagley, Troy, Annett, Yu and Conlan) are listed at Radius Health Inc, Boston, where some authors of the 2011 report on RAD140 and all authors of the 2017 breast cancer paper are also listed.1,3,6 The PubMed record carries no funding statement.1 The registry lists Stemline Therapeutics, Inc., an industry sponsor, as lead sponsor.5
Findings. Twenty-two patients (21 AR+, heavily pretreated) received 50 mg (n = 6), 100 mg (n = 13) or 150 mg (n = 3) once daily.1 The most frequent adverse events were elevated AST (59.1%), ALT (45.5%) and total blood bilirubin (27.3%), and vomiting, dehydration, and decreased appetite and weight (27.3% each).1 Grade 3/4 adverse events occurred in 16 patients (72.7%), including elevated AST/ALT and hypophosphatemia (22.7% each); treatment-related events occurred in 17 of 22 (77.3%), 7 (31.8%) were grade 3 and none were grade 4.1 At the maximum tolerated dose of 100 mg/day, 1 patient with an ESR1 mutation at baseline had a partial response; overall, the clinical benefit rate at 24 weeks was 18.2% and median progression-free survival was 2.3 months.1 SHBG decreased in 18 of 18 patients and PSA increased in 16 of 20.1
Authors' conclusion and limits. The authors concluded that RAD140 is "a novel oral AR-targeted agent for the treatment of AR+/ER+/HER2- mBC with an acceptable safety profile and preliminary evidence of target engagement and antitumor activity".1 The PubMed record does not state limitations, discontinuations or deaths.1 The registry lists 20 enrolled where the paper reports 22.5,1
Deeper analysis: micro-dose excretion study in healthy men
Who and how. Wagener, Euler, Görgens, Guddat and Thevis of the German Sport University Cologne (Metabolites, 2022) ran six studies with five healthy men each, giving 1, 10 or 50 μg of RAD140 once or on five consecutive days, and analysed urine.2 The study was approved by the Ethics Committee of the German Sport University Cologne.2
Funding and ties. The paper states that the research "received funding from the Manfred-Donike Institute for Doping, Analysis (Cologne, Germany) and the Federal Ministry of the Interior of the Federal Republic of Germany", and the authors declare no conflict of interest.2
Findings. Maximum urinary concentrations after a single and after repeated dosing were 0.06 and 0.17 ng/mL at 1 μg and 4.6 and 11.6 ng/mL at 50 μg.2 The paper reports that concentrations peaked 2 to 6 hours after ingestion and that RAD140 remained detectable for up to 29 days after a single 50 μg dose.2
Authors' limits. The authors write that, because total metabolite concentrations were low and ratios varied between volunteers, "this method does not allow for a definitive statement about the time of intake and dose ingested", and that "additional elimination studies with higher doses of RAD140 may help in corroborating these threshold ratios".2
Doses reported in studies
| Source | Dose | Frequency | Length |
|---|---|---|---|
| Phase 1 trial in women with breast cancer1 | 50 mg (n = 6), 100 mg (n = 13), 150 mg (n = 3); maximum tolerated dose 100 mg/day | Once daily | Not given in the PubMed summary |
| Micro-dose excretion study, healthy men2 | 1, 10 or 50 μg | Once, or on 5 consecutive days | Single dose or 5 days |
| Case report, Alpha Bolic and Alpha Elite products10 | 20 mg RAD-140 a day (2 capsules of 10 mg), then 15 mg RAD-140 and 10 mg LGD-4033 a day (2 capsules of 7.5 mg and 5 mg); capsule contents as stated in the report | Daily | 4 weeks, then 3 weeks |
| Case report, RAD-14011 | Up to 15 mg | Daily | 5 weeks |
| Mouse study, female mice7 | 5 mg/kg | Not given in the PubMed summary | 10 weeks |
| Mouse study, older male and female mice8 | 5 mg/kg/day | Daily | 6 weeks |
Side effects reported
Sources in this part
In the phase 1 trial of 22 women, the most frequent adverse events were elevated AST (59.1%), ALT (45.5%) and total bilirubin (27.3%), with vomiting, dehydration, and decreased appetite and weight at 27.3% each.1 Grade 3/4 adverse events occurred in 16 patients (72.7%).1
Case reports: liver
Eight case reports in the sources listed here describe liver injury in people who reported using RAD-140 or a product containing it.10,11,12,4,18,19,20,21 In the 52-year-old man (also using LGD-4033 in one product, and reporting daily alcohol), liver enzymes returned to normal about 3 months after stopping; in the 26-year-old man, AST, ALT and total bilirubin were normal 1 month after discharge; in the 43-year-old man, liver biochemistry was back within reference ranges 5 months after stopping.10,12,4
Leung and colleagues (Ochsner J, 2022) report that symptoms and liver injury in the 24-year-old man resolved after cessation of the offending agent.11 Their full text states that at his most recent clinic visit, up to 5 months after discharge, his symptoms had entirely resolved and his liver tests had markedly improved, and that he did not return for his next scheduled visit.11
Mohamed and colleagues (Cureus, 2023) describe a 22-year-old man who reported taking RAD-140 for 16 weeks and had a total bilirubin of 427.5 µmol/L at presentation.18 Demangone and colleagues (Cureus, 2024) describe a 29-year-old man with jaundice and elevated liver enzymes after three months of RAD-140 use, whose symptoms resolved after discontinuing it.19 Niazi and colleagues (ACG Case Rep J, 2025) describe an atypical case of prolonged cholestasis caused by RAD-140 that was successfully managed with corticosteroids.20
Dao and colleagues (Proc Bayl Univ Med Cent, 2026) describe severe cholestatic liver injury in a previously healthy young man after use of a supplement containing RAD-140 and Andarin (S4), with progressive hyperbilirubinemia requiring plasmapheresis despite drug cessation and corticosteroid therapy, and a course complicated by pancreatitis and acute kidney injury requiring intensive care.21 The authors write that the case "represents the most severe manifestation of RAD-140-associated liver injury reported to date".21
Perananthan and George (Australian Prescriber, 2024) report a total serum bilirubin of 708 micromol/L at admission and note that it was reported to the Therapeutic Goods Administration as an adverse drug reaction.4
Case reports: heart and hormones
Padappayil and colleagues (Cureus, 2022) describe possible acute myocarditis in a 32-year-old man, and Schwartzman and colleagues (JACC: Case Reports, 2024) describe myopericarditis in a 16-year-old boy a few hours after his first and only dose of a product in a "RAD-140" fitness program.13,14 The 32-year-old also had type 1 diabetes and past cocaine and heroin use, and his troponin I peaked at 100.5 ng/mL; the 16-year-old's troponin was 4,690 ng/L then 6,066 ng/L, and it normalized after 2 weeks.13,14 Chong and colleagues (JCEM Case Reports, 2024) describe bilateral gynecomastia and hypogonadotropic hypogonadism in a man who used three supplements that contained RAD-140, MK-677 and cardarine, with undisclosed hormones also detected, and report full resolution after stopping them.15
Skorupski and colleagues (Pol Arch Intern Med, 2024) titled their case report "Selective androgen receptor modulator abuse-induced heart failure: catastrophic effects of RAD-140 (Testolone)"; the PubMed record shows no summary text, so no patient details are given here.22
The FDA's December 2025 warning letter to a seller of products marketed as SARMs states that "life-threatening reactions, including liver toxicity, have occurred in people taking products containing SARMs" and that "SARMs also have the potential to increase the risk of heart attack and stroke"; the products it names include Ostarine MK-2866, MK-677 Ibutamoren, Cardarine GW501516 and LGD-4033 Ligandrol, and it does not name RAD140.16
Bloodwork and markers
The app lists total testosterone, lipids and liver enzymes as markers to monitor for RAD-140. The phase 1 trial reported AST, ALT and total bilirubin elevations as its most frequent adverse events, and used SHBG and PSA as surrogate markers of androgen receptor engagement: SHBG decreased in 18 of 18 patients and PSA increased in 16 of 20.1 The case reports describe cholestatic or mixed liver values, and the Chong report describes biochemical hypogonadotropic hypogonadism in a man whose supplements contained RAD-140 along with other ingredients.10,11,4,15
Regulatory and anti-doping status
RAD140 is named in section S1.2, other anabolic agents, of the WADA 2026 Prohibited List, in the list of SARMs "e.g. andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23 and YK-11".17 S1.2 sits under "substances and methods prohibited at all times", which means prohibited in and out of competition, and the list came into effect on 1 January 2026.17 Wagener and colleagues add that WADA "has included SARMs in the Prohibited List since 2008".2
Papers describe RAD-140 or the class as unapproved: "a so-far unapproved SARM" (Wagener and colleagues, 2022), SARMs whose "use in clinical practice remains unapproved by the US Food and Drug Administration (FDA)" (Barbara and colleagues, 2020), and "SARMs are not approved by the TGA" (Perananthan and George, 2024).2,10,4
What is not known
Sources in this part
The sources listed here give no plasma time to peak and no oral bioavailability percentage for RAD-140 in people, and the app's 95% bioavailability, 2-hour time to peak and 5-day duration of activity have no cited measurement beside them here.1 Searching PubMed as described above returned 49 records, and none of their titles reports a controlled trial of RAD140 in healthy people; ClinicalTrials.gov returned one RAD140 study, in breast cancer. The one trial report is a phase 1 study of 22 women with metastatic breast cancer, and the PubMed summary of it gives no discontinuations, deaths or limitations.1 Studies in mice give mixed results, including increased frailty and mortality risk in female mice and preserved lean mass in older male mice, and none of them is a study in people.7,8
Frequently asked questions
What is the half-life of RAD-140?
The app lists the half-life of RAD-140 as about 60 hours (2.5 days), while the phase 1 trial in 22 women with metastatic breast cancer reported 44.7 hours.1 Wagener and colleagues cite the trial as "a half-life of 45 h".2 RAD140 was detectable in urine for up to 29 days after a single 50 μg dose, which is a detection time, not a half-life.2
What is RAD-140?
RAD-140, also called testolone, is an oral, nonsteroidal selective androgen receptor modulator reported by Miller and colleagues, with authors listed at Radius Health, in ACS Medicinal Chemistry Letters.3,4 Its trial use so far, in the sources listed here, is a phase 1 study in postmenopausal women with ER+/HER2- metastatic breast cancer.1
Is RAD-140 FDA approved?
Is RAD-140 banned by WADA?
RAD140 is named in section S1.2 of the WADA 2026 Prohibited List, which is prohibited at all times, in and out of competition.17
Does RAD-140 cause liver problems?
In the phase 1 trial, elevated AST (59.1%), ALT (45.5%) and total bilirubin (27.3%) were the most frequent adverse events among 22 women.1 Eight case reports from 2020 to 2026 describe liver injury in people who used RAD-140 or a product containing it, one of them with LGD-4033 and daily alcohol and one with Andarin (S4); they are single-patient reports, and the courses ranged from normal liver tests 1 month after discharge to plasmapheresis and intensive care.10,11,12,4,18,21
Has RAD-140 been tested in people?
How long can RAD-140 be detected in urine?
What doses have been reported in RAD-140 studies?
Guides, tools and comparisons
References
- LoRusso P, Hamilton E, Ma C, et al. A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer. Clin Breast Cancer 2022. PMID 34565686
- Wagener F, Euler L, Görgens C, et al. Human In Vivo Metabolism and Elimination Behavior of Micro-Dosed Selective Androgen Receptor Modulator RAD140 for Doping Control Purposes. Metabolites 2022. PMC9325264
- Miller CP, Shomali M, Lyttle CR, et al. Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. ACS Med Chem Lett 2011. PMID 24900290
- Perananthan V, George J. Severe liver injury following use of RAD-140, a selective androgen receptor modulator, for body building. Aust Prescr 2024. PMC10911832
- Stemline Therapeutics, Inc. Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer. ClinicalTrials.gov NCT03088527, record updated 2022. NCT03088527
- Yu Z, et al. Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action. Clin Cancer Res 2017. PMID 28974548
- Brown AM, et al. RAD140 (Testolone) negatively impacts skeletal muscle adaptation, frailty status and mortality risk in female mice. Clin Exp Pharmacol Physiol 2023. PMID 37758180
- Heinze SS, et al. The impact of a selective androgen receptor modulator (RAD140) on frailty and underlying mechanisms in older male and female C57Bl/6 mice. Mech Ageing Dev 2025. PMID 40158703
- Puskas J, Guda T, Niccoli S, et al. Preclinical assessment of the selective androgen receptor modulator RAD140 to increase muscle mass and bone mineral density. Physiol Rep 2025. PMC12274021
- Barbara M, et al. Drug-Induced Liver Injury Associated With Alpha Bolic (RAD-140) and Alpha Elite (RAD-140 and LGD-4033). ACG Case Rep J 2020. PMC7535764
- Leung K, et al. RAD-140 Drug-Induced Liver Injury. Ochsner J 2022. PMC9753945
- Ladna M, et al. Idiosyncratic drug-induced liver injury related to use of novel selective androgen receptor modulator RAD140 (Testalone): a case report. J Med Case Rep 2023. PMC10054042
- Padappayil RP, et al. Acute Myocarditis From the Use of Selective Androgen Receptor Modulator (SARM) RAD-140 (Testolone). Cureus 2022. PMC8881971
- Schwartzman KH, et al. Myopericarditis Following Use of Selective Androgen Receptor Modifier "RAD-140". JACC Case Rep 2024. PMC11328744
- Chong S, et al. Reversible Gynecomastia and Hypogonadism Due to Usage of Commercial Performance-Enhancing Supplement Use. JCEM Case Rep 2024. PMID 39145153
- U.S. Food and Drug Administration. Warning Letter to Dynamic Health Group dba SARMS AMERICA, MARCS-CMS 719257, 12 December 2025. FDA warning letter
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA 2026. WADA 2026 list
- Mohamed WT, Jahagirdar V, Fatima I, et al. Selective Androgen Receptor Modulators (SARMs)-Induced Liver Injury: A Case Report and Review of Literature. Cureus 2023. PMID 36945289
- Demangone MR, Abi Karam KR, Li J. Selective Androgen Receptor Modulators Leading to Liver Injury: A Case Report. Cureus 2024. PMID 39328701
- Niazi B, Quach B, Fisher K, et al. Cholestatic Drug-Induced Liver Injury From Rad-140 Successfully Treated With Corticosteroids. ACG Case Rep J 2025. PMID 40761329
- Dao D, King B, Dao H, et al. Unregulated gains: a case of RAD-140-induced liver injury. Proc (Bayl Univ Med Cent) 2026. PMID 42417499
- Skorupski WJ, Marko A, Janus M, et al. Selective androgen receptor modulator abuse-induced heart failure: catastrophic effects of RAD-140 (Testolone). Pol Arch Intern Med 2024. PMID 38864168